Technical Analysis for OVID - Ovid Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.8 | 1.82% | 0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Historical OVID trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Weak, Overbought and Reversal Signs | Reversal | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | about 19 hours ago | |
| 3x Volume Pace | about 19 hours ago | |
| Up 5% | about 19 hours ago | |
| Possible Pocket Pivot | about 19 hours ago | |
| Up 10% | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 03/12/2020
Ovid Therapeutics Inc. Description
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Symptoms Neurological Disorders Epilepsy Syndromes Takeda Pharmaceutical Company Urological Disorders Genodermatoses Fragile X Syndrome Sedatives Anticonvulsants Rare Neurological Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.4 |
| 52 Week Low | 1.8 |
| Average Volume | 2,030,226 |
| 200-Day Moving Average | 5.21 |
| 50-Day Moving Average | 3.50 |
| 20-Day Moving Average | 2.50 |
| 10-Day Moving Average | 2.59 |
| Average True Range | 0.21 |
| ADX | 26.0 |
| +DI | 30.24 |
| -DI | 17.29 |
| Chandelier Exit (Long, 3 ATRs ) | 2.46 |
| Chandelier Exit (Short, 3 ATRs ) | 2.87 |
| Upper Bollinger Band | 2.76 |
| Lower Bollinger Band | 2.24 |
| Percent B (%b) | 1.08 |
| BandWidth | 20.62 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.26 |
| MACD Histogram | 0.1142 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.30 | ||||
| Resistance 3 (R3) | 3.33 | 3.21 | 3.21 | ||
| Resistance 2 (R2) | 3.21 | 3.08 | 3.19 | 3.18 | |
| Resistance 1 (R1) | 3.00 | 3.00 | 2.97 | 2.97 | 3.16 |
| Pivot Point | 2.88 | 2.88 | 2.86 | 2.86 | 2.88 |
| Support 1 (S1) | 2.67 | 2.75 | 2.64 | 2.64 | 2.44 |
| Support 2 (S2) | 2.55 | 2.67 | 2.53 | 2.42 | |
| Support 3 (S3) | 2.34 | 2.55 | 2.39 | ||
| Support 4 (S4) | 2.31 |
